About VenoStent
VenoStent is a private company based in Houston, Texas. It has reported $29,154,372 raised in six offerings on Form D since March 2018. Its chief executive is Timothy Boire.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 10, 2026 | May 1, 2026 | $10,000,000fully sold | 29 | $344K | Debt, OptionsRule 506(b) | Form D ↗ |
| Jul 5, 2023 | Jul 19, 2023 | $16,062,824of $21.1M target | 60 | $267K | EquityRule 506(b) | Form D ↗ |
| Jan 29, 2021 | Feb 16, 2021 | $2,242,619of $3.0M target | 24 | $93,442 | EquityRule 506(b) | Form D ↗ |
| May 26, 2020 | Jun 10, 2020 | $515,000of $535K target | 16 | $32,188 | OptionsRule 506(b) | Form D ↗ |
| Jun 25, 2019 | Jul 10, 2019 | $263,929of $300K target | 8 | $32,991 | EquityRule 506(b) | Form D ↗ |
| Mar 7, 2018 | Mar 22, 2018 | $70,000of $400K target | 4 | $17,500 | Debt, OptionsRule 506(b) | Form D ↗ |
| Total, six offerings | $29,154,372 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on VenoStent's Form D filed May 1, 2026.
JW
JM
RC
Robert Crutchfield
Director
Also a director at OrbitalRx and Pleural Dynamics and an executive officer and director at Synaptrix.
Earlier filings also listed Kulika Weizman (director, last listed Feb 2021).